Notice: This company has been marked as potentially delisted and may not be actively trading. NASDAQ:ENZY (ENZY) (ENZY) Stock Price, News & Analysis Add Share Share Stock Analysis Stock Analysis About (ENZY) Stock (NASDAQ:ENZY) 30 days 90 days 365 days Advanced Chart Ad Porter & CompanyWe recommended Nvidia in 2016, now we’re recommending this…The Pentagon has just made a critical $7.7 billion move. They're investing into one of the most controversial technologies the world has ever known… A technology I’m calling “The AI Keystone”, because without it, the AI industry is doomed.Click here to watch his special investigative report into the controversial ‘AI Keystone’. Get (ENZY) alerts:Sign Up Key Stats Today's Range$11.85▼$11.8550-Day Range N/A52-Week Range$6.30▼$12.35VolumeN/AAverage Volume120,557 shsMarket CapitalizationN/AP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company OverviewEnzymotec Ltd. is a nutritional ingredients and medical foods company. The Company's technologies, research expertise and clinical validation process enables it to develop solutions across a range of products. The Company operates in two segments: Nutrition segment and VAYA Pharma segment. Both of the Company's segments offer a range of products that leverage its lipid-related offerings. Its product suite addresses the entire human life-cycle, from infancy to old age, and comprises ingredients in products ranging from infant formula to nutritional supplements, as well as branded medical foods, sold only under a doctor's supervision. It markets its product portfolio to established global consumer companies and physicians and target large and growing consumer health and wellness markets. The Company's clinically-validated products include bio-functional lipid-based compounds designed to address dietary needs, medical disorders and common diseases.Read More… We recommended Nvidia in 2016, now we’re recommending this… (Ad)The Pentagon has just made a critical $7.7 billion move. They're investing into one of the most controversial technologies the world has ever known… A technology I’m calling “The AI Keystone”, because without it, the AI industry is doomed.Click here to watch his special investigative report into the controversial ‘AI Keystone’. Receive ENZY Stock News and Ratings via Email Sign-up to receive the latest news and ratings for (ENZY) and its competitors with MarketBeat's FREE daily newsletter. Email Address ENZY Stock News Headlines13 Days After Meeting, She Proposed on TV and He Followed SuitOctober 4, 2024 | nytimes.comInternational Makeup Artist Bubah Gets Emotional After Meeting Alia Bhatt, Aishwarya Rai Bachchan At Paris Fashion Week 2024 (VIDEO)September 24, 2024 | msn.comTrump’s IRS Hands Massive ‘Victory Gift’ To 401K OwnersThe "Fake Media" has completely ignored Trump's genius "victory gift" to all America First patriots like you. A tax-free gift so powerful it could reshape the financial destinies of millions of IRA and 401(k) owners…November 7, 2024 | Colonial Metals (Ad)Calliditas Announces Positive Data From Proof-of-concept Phase 2 Trial With SetanaxibMay 6, 2024 | markets.businessinsider.comEnzymatica AB: Enzymatica Interim report Q1/2024: MDR certification opens up great commercial opportunitiesApril 25, 2024 | finanznachrichten.deNotice of Annual General Meeting 2024 in Enzymatica AB (publ)March 27, 2024 | finance.yahoo.comEnzymatica wins CE-certification for nasal spray ColdZymeMarch 13, 2024 | msn.com32 top US cities to have a catMarch 4, 2024 | msn.comSee More Headlines ENZY Stock Analysis - Frequently Asked Questions How were (ENZY)'s earnings last quarter? (ENZY) (NASDAQ:ENZY) issued its quarterly earnings results on Wednesday, May, 17th. The biotechnology company reported $0.03 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.06 by $0.03. (ENZY)'s quarterly revenue was down 14.3% compared to the same quarter last year. What other stocks do shareholders of (ENZY) own? Based on aggregate information from My MarketBeat watchlists, some other companies that (ENZY) investors own include Caesarstone (CSTE), Laredo Petroleum (LPI), Allena Pharmaceuticals (ALNA), Camtek (CAMT), Arbutus Biopharma (ABUS), Ampliphi Biosciences (APHB) and Aquinox Pharmaceuticals (AQXP). Company Calendar Last Earnings5/17/2017Today11/07/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorN/A Industry N/A Sub-IndustryN/A Current SymbolNASDAQ:ENZY CUSIPN/A CIK1578809 Webwww.enzymotec.com Phone+972-7-47177177FaxN/AEmployeesN/AYear FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding SharesN/AFree FloatN/AMarket CapN/A OptionableNot Optionable BetaN/A The Next 7 Blockbuster Stocks for Growth InvestorsWondering what the next stocks will be that hit it big, with solid fundamentals? Click the link below to learn more about how your portfolio could bloom.Get This Free Report This page (NASDAQ:ENZY) was last updated on 11/7/2024 by MarketBeat.com Staff From Our Partners626 winning trades out of 647…Imagine turning nearly every Friday into a payday. That's exactly what one reclusive multi-millionaire trad...Investing Daily | SponsoredThe Final FrontierAnd a lot of powerful investors would rather this exposé never saw the light of day. I suspect they’ll attempt...Porter & Company | SponsoredWARNING: “Buffett Indicator” flashing for first time in 50 yearsWarren Buffett has sold a staggering $97 billion worth of stocks this year... But why? Our research indi...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding (ENZY) Please log in to your account or sign up in order to add this asset to your watchlist. Share (ENZY) With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.